Background: Inhibitors of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have been used in the treatment of relapsed and refractory Hodgkin's lymphoma (R/R HL) recently. To further understand the safety and efficacy of PD-1/PD-L1 inhibitors in R/R HL, we conducted this meta-analysis.
An overview of asthma and COPD, including symptoms and diagnosis.
Gilead Sciences, Inc.has announced that the European Commission has granted marketing authorization for the once-daily single tablet regimen (STR) Odefsey...
EMA has been advised by RepliGen of its decision to withdraw its application for SecreFlo (synthetic secretin human) as an...
Novartis announced that results of a global Phase III study (EVOLVE-1) showed that Afinitor (everolimus) did not extend overall survival...
Zhejiang Huahai Pharmaceutical has agreed with Breckenridge Pharmaceutical to market, in the USA, a generic version of Viramune (nevirapine) currently...
BMS and Pfizer have launched their oral direct Factor Xa inhibitor, Eliquis (apixaban), in the UK for the prevention of...